News

Age should not be the sole reason that potentially helpful disease-modifying therapies are withheld among older patients with ATTR-CM.

Certain body mass assessments were associated with long-term patient outcomes in cardiac amyloidosis.

The use of therapies specific to the disease processes in ATTR-CM is an excellent strategy to arrive at better outcomes.

Age appears to have an impact in cardiac biomarker levels in patients with wild-type ATTR-CM while sex correlates with the age of diagnosis.

Lifestyle factors may contribute to the development of wild-type ATTR-CM via oxidative stress.

A review highlights the many roles of transthyretin in the body and the potential implications of long-term suppression in patients with ATTR.

A minimally invasive technique for treating mitral valve regurgitation was found to work successfully in patients with ATTR-CM.

A genetic variant linked to ATTR-CM was more common in Hispanic individuals with more African ancestry, especially Dominican descent.

In a recent webinar, Kristen Hsu of the Amyloidosis Research Consortium discussed the clinical trials currently being conducted for ATTR-CM.

People living with ATTR-CM often experience high levels of anxiety and depression that have an impact on their physical health.